I. COMMENCED TRADING IN AUGUST | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/ Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
INITIAL OFFERINGS | ||||||||
There were no initial public offerings that commenced in August. | ||||||||
Total: $0M Number of IPOs in August: 0 Average value of August IPOs: $0M Number of IPOs in 2011: 10 Total raised in IPOs in 2011: $516.84M Average value of IPOs in 2011: $51.68M | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/ Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
FOLLOW-ON OFFERINGS | ||||||||
Somaxon Pharmaceuticals Inc. (San Diego; SOMX) |
8/3/11 |
8/3/11 |
N/A |
N/A |
N/A |
Citadel Securities LLC |
$30 |
N/A |
Total: $30M Number of follow-on offerings in August: 1 Average value of August follow-ons: $30M Number of follow-on offerings in 2011: 57 Total raised in follow-ons in 2011: $4,288.716M Average value of follow-ons in 2011: $75.24M | ||||||||
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. |
II. FILED AND PENDING |
||||||||
Company (Symbol)# |
Date Filed |
Shares/Units (M) |
Price |
Shares Out |
Lead, Other Underwriters (M)@ |
Gross (US$M) |
||
INITIAL OFFERINGS | ||||||||
Argos Therapeutics Inc. (Durham, N.C.; ARGS) |
7/29/11 |
N/A |
N/A |
N/A |
Lazard Capital Markets Canaccord Genuity (co-lead) Needham & Co. BMO Capital Markets |
$86.25 |
||
Clovis Oncology Inc. (Boulder, Colo.; CLVS) |
6/23/11 |
N/A |
N/A |
N/A |
J.P. Morgan Credit Suisse (co-lead) Leerink Swann |
$149.5 |
||
Cutanea Life Sciences Inc. (CTNA) |
11/5/10 |
2.3S |
$6-$7 |
3.9 |
Brean Murray, Carret & Co. Rodman & Renshaw LLC (co-lead) |
$14.95 |
||
Insys Therapeutics Inc. (Phoenix; INRX) |
3/30/11 |
N/A |
N/A |
N/A |
Wells Fargo Securities JMP Securities (co-lead) Oppenheimer & Co. |
$55 |
||
Merrimack Pharmaceuticals Inc. (Cambridge, Mass.; MACK) |
7/8/11 |
N/A |
N/A |
N/A |
J.P. Morgan BofA Merrill Lynch Cowen & Co. Oppenheimer & Co. |
$172.5 |
||
NewLink Genetics Corp. (NLNK) |
12/21/10 |
N/A |
N/A |
N/A |
Wells Fargo Cowen & Co. (co-lead) Robert W. Baird Canaccord Genuity Needham & Co. LLC |
$86.25 |
||
Supernus Pharmaceuticals Inc. (SUPN) |
12/23/10 |
N/A |
N/A |
N/A |
Citibank Barclays Capital (co-lead) Cowen and Co. Stifel Nicolaus Weisel |
$100 |
||
FOLLOW-ON OFFERINGS | ||||||||
Zogenix Inc. (San Diego; ZGNX)1 |
8/25 |
12S |
$3.40 |
N/A |
Leerink Swann LLC Wells Fargo Sec. LLC (co-lead) Stifel Nicolaus & Co. Inc. William Blair & Co. LLC Oppenheimer & Co. Inc. |
$40.8 |
||
Notes: p># Unless otherwise indicated, shares are traded on the Nasdaq exchange. General shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. N/A = Not available, applicable or reported. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. 1 Zogenix's overallotment option: 1.8M shares. |